Zeynep Kipriye1,
Behiye Senel2,
Evrim Yenilmez3 
For correspondence:- Evrim Yenilmez Email: evrimakyil@anadolu.edu.tr Tel:+905325575409
Accepted: 22 August 2017 Published: 30 September 2017
Citation: Kipriye Z, Senel B, Yenilmez E. Preparation and evaluation of carvedilol-loaded solid lipid nanoparticles for targeted drug delivery. Trop J Pharm Res 2017; 16(9):2057-2068 doi: 10.4314/tjpr.v16i9.4
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To develop suitable solid lipid nanoparticles (SLN) containing carvedilol (CL) for controlled delivery to site of action.
Methods: Solid lipid nanoparticles (SLNs) containing carvedilol (CL) were prepared by hot homogenization and ultrasonication methods. The SLNs were characterized in terms of entrapment efficiency, particle size, zeta potential, polydispersity index, cytotoxicity, solid state characterization and drug release. The stability of the formulations was investigated by monitoring their properties for a period of 3 months.
Results: The mean size of the nanoparticles was in the range of 130.70 ± 1.80 to 154.40 ± 2.40 nm. Solid state analysis showed that carvedilol was uniformly dispersed in the lipid nanoparticles. Drug entrapment efficiency ranged from 96.03 ± 0.13 to 93.46 ± 0.21 % while in vitro cumulative drug release from the nanoparticles in simulated intestinal fluid (SIF) and phosphate buffer containing 30% PEG (pH 6.8) was 96.57 ± 0.40 and 75.13 ± 0.15 %, respectively, at the end of 24 h. In vitro release of carvedilol from SLNs followed fist order kinetics and Higuchi diffusion model.
Conclusion: The SLNs developed in this study represent a promising safe system for the sustained and controlled delivery of carvedilol.
Archives
News Updates
Fulltext in PDF